Due to an improvement in surgical techniques, a neoadjuvant systemic therapy that includes checkpoint inhibitors in triple-negative breast cancer patients and dual HER2-directed therapy in HER2-positive breast cancer patients leads to an improved pCR plus advances in radiation therapy which have changed the outcome of breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.